Richard G. Stock, MD, senior faculty, Radiation Oncology, Mount Sinai Hospital, discusses the optimal use of radium-223 dichloride (Xofigo) for the treatment of patients with metastatic castration-resistant prostate cancer.
Richard G. Stock, MD
Advertisement
Articles by Richard G. Stock, MD
Advertisement
Latest Updated Articles
Dr. Stock on the Optimal Use of Radium-223 in mCRPCPublished: April 25th 2016 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
HPV Vaccination and Evolving Screening Strategies Continue to Shape Cervical Cancer Prevention Efforts
3
The OncFive: Top Oncology Articles for the Week of 1/25
4
FDA Approval Sought for Lirafugratinib in Second-Line, FGFR2-Altered Cholangiocarcinoma
5